Abstract: Methods for monitoring a patient's level of B-type natriuretic peptide (BNP), and implantable cardiac systems capable of performing such methods, are provided. A ventricle is paced for a period of time to provoke a ventricular evoked response, and a ventricular intracardiac electrogram (IEGM) indicative of the ventricular evoked response is obtained. Based on the ventricular IEGM, there is a determination of at least one ventricular evoked response metric (e.g., ventricular evoked response peak-to-peak amplitude, ventricular evoked response area and/or ventricular evoked response maximum slope), and the patient's level of BNP is monitored based on determined ventricular evoked response metric(s). Based on the monitored level's of BNP, the patients heart failure (HF) condition and/or risks and/or occurrences of certain events (e.g., an acute HF exacerbation and/or an acute myocardial infarction) can be monitored.

Abstract: An exemplary includes acquiring an electroneurogram of the right carotid sinus nerve or the left carotid sinus nerve, analyzing the electroneurogram for at least one of chemosensory information and barosensory information and calling for one or more therapeutic actions based at least in part on the analyzing. Therapeutic actions may aim to treat conditions such as sleep apnea, an increase in metabolic demand, hypoglycemia, hypertension, renal failure, and congestive heart failure. Other exemplary methods, devices, systems, etc., are also disclosed.

Abstract: An exemplary includes acquiring an electroneurogram of the right carotid sinus nerve or the left carotid sinus nerve, analyzing the electroneurogram for at least one of chemosensory information and barosensory information and calling for one or more therapeutic actions based at least in part on the analyzing. Therapeutic actions may aim to treat conditions such as sleep apnea, an increase in metabolic demand, hypoglycemia, hypertension, renal failure, and congestive heart failure. Other exemplary methods, devices, systems, etc., are also disclosed.

Abstract: Implantable systems, and methods for use therewith, enable the monitoring of a patient's electromechanical delay (EMD) and arterial blood pressure. Paced cardiac events are caused by delivering sufficient pacing stimulation to cause capture. A cardiogenic impedance (CI) signal, indicative of cardiac contractile activity in response to the pacing stimulation being delivered, is obtained. One or more predetermined features of the CI signal are detected, and a value indicative of the patient's EMD is determined by determining a time between a delivered pacing stimulation and at least one of the detected one or more features of the CI signal. The value indicative of EMD can be used to more accurately determine metrics indicative of pulse arrival time (PAT), which can be used to estimate arterial blood pressure.

Abstract: Detecting patterns in sensed implantable medical device (IMD) data is described. One implementation involves an IMD that includes a data-driven pattern detection network embodied on the IMD to detect a pattern from sensed patient data. The IMD also includes one or more algorithms embodied on the IMD to utilize the pattern to effect patient therapy.

Abstract: Embodiments of the present invention relate to implantable systems, and methods for use therein, that can detect T-wave alternans and analyze the detected alternans to provide information regarding cardiac instabilities and predict impending arrhythmias.

Abstract: A device, such as an implantable cardiac device, and method for switching between arrhythmia prevention modes is disclosed. The method includes monitoring an electrocardiogram (EGM) of the heart, determining whether the heart is in a normal sinus rhythm or in an abnormal rhythm, delivering pacing pulses at a first rate to either an atrium or a ventricle when the heart is in a normal sinus rhythm, and delivering pacing pulses to a ventricle at a second rate when the heart is in an abnormal rhythm, such as an atrial arrhythmia. The first rate is selected to minimize the occurrence of premature ventricular contractions, and the second rate is selected to both minimize the occurrence of premature ventricular contractions and minimize the occurrence of premature conducted beats.

Abstract: Implantable systems, and methods for use therein, for monitoring for mitral valve regurgitation (MR) are provided. An electrogram (EGM) signal and a corresponding pressure signal are obtained, where the EGM signal is representative of electrical functioning of the patient's heart during a plurality of cardiac cycles, and the corresponding pressure signal is representative of pressure within the left atrium the patient's heart during the cardiac cycles. Windows of the pressure signal are defined, based on events detected in the EGM signal, and measurements from the windows are used to monitor for MR.

Abstract: A morphology discrimination scheme extracts shape characteristics from cardiac signals and identifies an associated cardiac condition based on the shape characteristics. For example, internal data structures may be updated to match the shape characteristics of a known condition (e.g., a patient's normal sinus rhythm). Similarly acquired shape characteristics obtained in conjunction with a later event (e.g., QRS complexes acquired during a tachycardia episode) may be compared with the previously stored shape characteristics to characterize the later event. In some aspects the shape characteristics relate to inflection points of cardiac signals.